Trends in outcomes of women with myocardial infarction undergoing primary angioplasty-Analysis of randomized trials.
mortality
myocardial infarction
outcome
primary PCI
therapy management
trends
women
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
05
2022
accepted:
07
12
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Sex- and gender-associated differences determine the disease response to treatment. The study aimed to explore the hypothesis that progress in the management of STE-myocardial infarction (STEMI) overcomes the worse outcome in women. We performed an analysis of three randomized trials enrolling patients treated with primary PCI more than 10 years apart. PRAGUE-1,-2 validated the preference of transport for primary PCI over on-site fibrinolysis. PRAGUE-18 enrollment was ongoing at the time of the functional network of 24/7PCI centers, and the intervention was supported by intensive antiplatelets. The proportion of patients with an initial Killip ≥ 3 was substantially higher in the more recent study (0.6 vs. 6.7%, The prognosis of women with MI treated with primary PCI improved substantially with 24/7 regional availability of mechanical reperfusion, performance-enhancing technical progress, and intensive adjuvant antithrombotic therapy. A major modifiable hindrance to achieving this benefit in a broad population of women is the timely diagnosis by health professional services.
Sections du résumé
Background
UNASSIGNED
Sex- and gender-associated differences determine the disease response to treatment.
Aim
UNASSIGNED
The study aimed to explore the hypothesis that progress in the management of STE-myocardial infarction (STEMI) overcomes the worse outcome in women.
Methods and results
UNASSIGNED
We performed an analysis of three randomized trials enrolling patients treated with primary PCI more than 10 years apart. PRAGUE-1,-2 validated the preference of transport for primary PCI over on-site fibrinolysis. PRAGUE-18 enrollment was ongoing at the time of the functional network of 24/7PCI centers, and the intervention was supported by intensive antiplatelets. The proportion of patients with an initial Killip ≥ 3 was substantially higher in the more recent study (0.6 vs. 6.7%,
Conclusion
UNASSIGNED
The prognosis of women with MI treated with primary PCI improved substantially with 24/7 regional availability of mechanical reperfusion, performance-enhancing technical progress, and intensive adjuvant antithrombotic therapy. A major modifiable hindrance to achieving this benefit in a broad population of women is the timely diagnosis by health professional services.
Identifiants
pubmed: 36684569
doi: 10.3389/fcvm.2022.953567
pmc: PMC9845716
doi:
Types de publication
Journal Article
Langues
eng
Pagination
953567Informations de copyright
Copyright © 2023 Motovska, Hlinomaz, Aschermann, Jarkovsky, Želízko, Kala, Groch, Svoboda, Hromadka and Widimsky.
Déclaration de conflit d'intérêts
JJ was employed by Institute of Biostatistics and Analyses Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2013 Dec 7;382(9908):1879-88
pubmed: 24007976
J Am Coll Cardiol. 2015 Nov 3;66(18):1961-1972
pubmed: 26515998
Circulation. 2006 May 23;113(20):2398-405
pubmed: 16702474
Eur Heart J Acute Cardiovasc Care. 2019 Apr;8(3):283-290
pubmed: 30406673
Eur Heart J. 2020 Sep 1;41(33):3117-3121
pubmed: 32531027
Heart. 2008 Mar;94(3):e5
pubmed: 17693459
Eur Heart J. 2003 Jan;24(1):94-104
pubmed: 12559941
Lancet. 2019 Oct 19;394(10207):1415-1424
pubmed: 31500849
Circulation. 2003 Mar 25;107(11):1463-6
pubmed: 12654599
Cardiovasc Res. 2017 Jun 1;113(7):711-724
pubmed: 28472454
BMJ Open. 2017 Sep 21;7(9):e015241
pubmed: 28939567
Crit Care. 2013 Sep 27;17(5):239
pubmed: 24093465
Heart. 2017 Oct;103(20):1625-1630
pubmed: 28784665
J Am Coll Cardiol. 2022 Apr 12;79(14):1407-1425
pubmed: 35393023
J Am Heart Assoc. 2017 Jan 11;6(1):
pubmed: 28077385
Circ Res. 2019 Jul 5;125(2):245-258
pubmed: 31268854
BMJ Open. 2018 May 3;8(5):e020211
pubmed: 29724738
J Am Heart Assoc. 2019 May 21;8(10):e012161
pubmed: 31092091
Eur Heart J. 2018 Dec 21;39(48):4239-4242
pubmed: 29850788
JAMA Intern Med. 2018 May 1;178(5):632-639
pubmed: 29630703
CJC Open. 2021 Jan 23;3(6):723-732
pubmed: 34169251
Coron Artery Dis. 2017 Aug;28(5):417-425
pubmed: 28489635
Eur Heart J. 2000 May;21(10):823-31
pubmed: 10781354
Medicine (Baltimore). 2018 Jul;97(30):e11644
pubmed: 30045311
Circulation. 2016 Nov 22;134(21):1603-1612
pubmed: 27576777
Circulation. 2021 Feb 16;143(7):e239-e248
pubmed: 32954796
Circulation. 2019 Feb 19;139(8):1047-1056
pubmed: 30586725
Circulation. 2021 Feb 16;143(7):685-695
pubmed: 33587654
JAMA Intern Med. 2014 Nov;174(11):1822-30
pubmed: 25265319
FASEB J. 2017 Jan;31(1):29-34
pubmed: 27682203
Lancet. 2021 Jun 19;397(10292):2385-2438
pubmed: 34010613
J Am Coll Cardiol. 2018 Jan 30;71(4):371-381
pubmed: 29154813
Heart. 2004 Jan;90(1):99-106
pubmed: 14676259
Circulation. 2016 Mar 1;133(9):916-47
pubmed: 26811316
J Am Coll Cardiol. 1997 Jan;29(1):35-42
pubmed: 8996292
JAMA. 2018 May 22;319(20):2127-2128
pubmed: 29800163
J Am Heart Assoc. 2021 Jul 6;10(13):e019938
pubmed: 34155902
JAMA Cardiol. 2020 Aug 1;5(8):939-947
pubmed: 32432718
J Am Heart Assoc. 2019 Feb 19;8(4):e011190
pubmed: 30764687
Eur Heart J. 2020 Apr 1;41(13):1328-1336
pubmed: 31876924